FDA Approves HALOPERIDOL DECANOATE — NorthStar RxLLC

# FDA Approves NorthStar RxLLC's Haloperidol Decanoate for Intramuscular Administration The FDA has approved NorthStar RxLLC's haloperidol decanoate intramuscular injection (ANDA216730), adding another generic option to the long-acting antipsychotic market and potentially intensifying pricing competition in this established therapeutic category. The approval enhances treatment accessibility for schizophrenia and other psychotic disorders while likely pressuring margins for existing haloperidol decanoate manufacturers.